Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
JNJ · against 589 other Healthcare companies listed in US-listed
Ranked #136 of 590 · scores higher than 76% of peers
Bars: peers in each 10-point band of the valuation score47 peers with a valuation score of 60–69, including JNJ · Click a bar to see the companies
Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | JNJ | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 3.3% | -4.4% | 80% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 5.4% | -1.2% | 71% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 3.6% | -2.2% | 73% | 20% | |
| Book yieldHigher is better · 582 reported | 13.7% | 26.1% | 31% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 292M USD | 98 | 80 | |
| 2 | 2.0B USD | 97 | 97 | |
| 3 | 658M USD | 96 | 97 | |
| 3 | 567M USD | 96 | 81 | |
| 3 | 384M USD | 96 | 57 | |
| 130 | 6.8B USD | 61 | 65 | |
| 130 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 1.2B USD |
| 61 |
| 48 |
| 136 | 784M USD | 60 | 34 |
| 136 | 22.9B USD | 60 | 60 |
| 136 | 622.8B USD | 60 | 59 |
| 136 | 1.8B USD | 60 | 79 |
| 136 | 5.1B USD | 60 | 61 |
| 141 | 170.8B USD | 59 | 46 |
| 141 | 49.1B USD | 59 | 47 |